Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC

Stefan Langhammer _ and Joachim Scheerer

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:43555-43570. https://doi.org/10.18632/oncotarget.16674

Metrics: PDF 1948 views  |   HTML 4703 views  |   ?  


Stefan Langhammer1 and Joachim Scheerer1

1 Life Science Consulting, Hirschweg, Burgwedel, Germany

Correspondence to:

Stefan Langhammer, email:

Keywords: NSCLC, targeted therapy, EGFR, angiogenesis

Received: December 16, 2016 Accepted: March 13, 2017 Published: March 29, 2017


In the light of current treatment developments for non-small cell lung cancer (NSCLC), the idea of a plastic cellular tumorigenic network bound by key paracrine signaling pathways mediating resistances to targeted therapies is brought forward. Based on a review of available preclinical and clinical data in NSCLC combinational approaches to address drivers of this network with marketed drugs are discussed. Five criteria for selecting drug combination regimens aiming at its disruption and thereby overcoming resistances are postulated.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16674